Inotek Pharmaceuticals Corp. (Nasdaq: ITEK) announced the Phase 3 development strategy for its glaucoma drug trabodenoson sending the stock price soaring $10.14 to close at $15.37.
Inotek announces development strategy
July 23, 2015 at 20:43 PM EDT
